Pfizer Vfend Approved For Candidemia
This article was originally published in The Pink Sheet Daily
Executive Summary
Supplemental indication is based on trial showing voriconazole was as effective as a regimen of amphotericin B followed by fluconazole. Pfizer may try to differentiate the product based on adverse event profile.